SGS Opens New Site in Belgium
SGS officially opened its new clinical pharmacology research center on the Antwerp University Hospital site on October 26, 2021, in the presence of Frankie Ng, SGS CEO.
The newly built SGS CPU, aimed at early phase research, is located next to the University Hospital of Antwerp (UZA). Its proximity to UZA reinforces scientific collaboration with a network of specialists and techniques.
This new CPU is a modern, sustainable, and innovative facility. With a capacity of 110 beds, a wide range of settings can be provided. Study participants stay in two to 8-person rooms, or in individual rooms, and have access to comfortable living and leisure areas. A high-care room allows follow-up during testing of new drugs. Two specialized quarantine units are available for controlled investigation of infection models or controlled human infection models (CHIM). In recent years, the SGS CPU has conducted the first malaria challenge studies in Belgium with its own developed H3N2 (flu) virus.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
